Global News Distribution

health

Life Coach Eric North, aka “The Happiness Warrior” Depicts the Art of Letting Go

New York City, March 7, 2024 (Global News Distribution) -

Life is a continuous journey full of ups and downs and sometimes, people need experts like Life Coach Eric North to guide them through the journey of life. Eric is best known as “The Happiness Warrior” who fights for people who struggling with mental health and helps them with his effective practices. He conveys the real meaning of a Warrior and shows the path to gain eternal happiness. However, the process is consistent and one must follow the practices to witness a change in life. Eric believes life is a grateful endeavor to be respected and appreciated at every step of the journey. Wisdom and self-awareness are the main elements to create a strong mentality and a better personality. A person who understands the meaning of being both purposeful and fulfilled can feel more content in life.

A lot of people have faced or facing darkness and despair in their lives, simply because they are not living fully. Poorly thought-out decisions can lead to pain which triggers a cycle of self-loathing. It is Repressed knowledge that it’s not something that anyone deserves or must accept as their reality. It requires taking an understanding of the inner light in subconsciousness which helps to guide even in the toughest times of life. Eric explains that it is the mindset and attitude that humans set. It helps to determine the destiny and achievements of lives that fulfill dreams. Every individual has ample potential in life to move on without any self-doubt but getting stuck in the past can lock away goals and desires which are needed to be achieved. Everything one needs to know is always right in front, but one must learn to tune in and listen to the universe. A person needs to learn to forgive and accept everything to proceed in life with more clarity and self-respect.

The self-created feelings of doubt and reliance on negative emotions harm one’s personal growth and undermine the right to be happy and free of self-imposed guilt. Being vulnerable and real helps to channel the real emotions in life. Most setbacks in life are caused by the inability to let go of the past and let go of the misguided notion that bygone actions define the present. It causes a person to suffer unnecessarily without fault or accountability. It’s an unnecessary and false deterrent that alters the human ability to feel connected with others. It causes people to become dependent on others, to think for all, and to make decisions. A lot of people try to cope with negative emotions by putting them aside and can fester and intensify. The self-destructive forces of victimhood and martyrdom are the path to more misery and self-created shame. They turn people away from what’s good in life and make them feel lonelier and more disconnected with each passing day. Eric says that the path ahead will never be easy until one can clear these negative pathways from their mindset.

Clarity and acceptance play an important role in healing and help to get rid of the self-induced harmful thinking that’s ingrained in society. One must learn to forgive themselves which makes them more empathetic and helps to address other’s feelings. It can help to broaden human perspective and create greater clarity in life where one is at peace with oneself. It can make a person more humble and help them say goodbye to the wounds of the past. Being ‘The Happiness Warrior’, Eric North has also shared the practices that can help people implement the art of letting go in their lives. He advises everyone to stop seeking perfection and seek clarity and truth. One must learn to use the word no, and how effective one becomes when one can state their feelings clearly. This is how humans learn to live in their truth without the need for validation from others.

Nothing beats fresh air and sunlight for creating an uplifted mood and improved physical health. That is why Eric asks everyone to embrace whatever weather is in store and learn to adapt with an attitude of acceptance. He believes that spending time exercising outdoors on a windy day is a guaranteed mood lifter. One must learn to break off all unhealthy relationships. People must be cautious in letting too many strangers become friends too quickly. It is important to listen and observe their actions before making quick decisions. Self-care and self-love are also a vital part of living where empathy and integrity are the most important self-created powers. So, one must learn to take care of oneself as well as others to achieve true happiness in life. Join a fruitful journey with Eric North, The Happiness Warrior who fights for everyone’s happiness. Visit http://www.thwarrior.com/ to know more.

Media Contacts:


Full Name
Company
Tom Estey Publicity & Promotion
Phone Number
518 248 6174
Website
https://thwarrior.com/
Email

Compose your email to at Tom Estey Publicity & Promotion.


  Spam Protection

May is Ultraviolet Awareness (UV) Month at Prevent Blindness, Designed to Educate the Public on the Best Ways to Keep Eyes Safe from UV Damage

April 25, 2022 (Global News Distribution) -

Prevent Blindness provides free, dedicated resources to encourage proper eye protection from negative effects of UV

As the warmer weather begins to encourage more outdoor activities, Prevent Blindness, the nation’s oldest eye health and safety organization, has declared May as Ultraviolet (UV) Awareness Month. The nonprofit group is seeking to educate the public on the negative effects of UV exposure to the eyes and vision, offering a dedicated webpage, PreventBlindness.org/sun-and-vision, downloadable fact sheets and shareable social media infographics.

There are two types of UV rays: UV-A and UV-B. Over time, the effects of UV rays may help cause a number of eye problems. UV-A rays may affect central vision. They can damage the macula, a part of the retina at the back of the eye. The front part of the eye (the cornea and the lens) absorbs most UV-B rays, but these rays may cause even more damage to the eyes than UV-A rays.

According to the Wilmer Eye Institute and Johns Hopkins Medicine, corneal damage, cataracts and macular degeneration are all possible chronic effects from UV exposure and can ultimately lead to decreased vision. Additionally, UV light is associated with skin cancers including squamous cell carcinomas, basal cell carcinomas, and cutaneous melanoma. Squamous cell carcinoma can occur not just on the skin, but on the conjunctiva and invade the cornea and inside of the eye, in some cases necessitating removal of the entire eye.

The Hidden Dangers of UV: Keeping Your Eyes Safe report from The Vision Council lists factors that put people’s eyes at greater risk of damage from UV exposure, including:

  •     Geography- In the United States, southern communities tend to receive more intense solar rays than northern ones. Elevation can also be a factor, since the thinner atmosphere at higher altitudes cannot absorb as much radiation. At the beach, sand or water can reflect up to 25% of UV; on a snow-covered surface, as much as 80% of UV may be reflected – adding to the initial exposure.
  •     Age- Children receive three times the annual sun exposure of adults, and research has shown that their young eyes are especially susceptible to UV-related harm. Unlike the mature lens of an adult eye, a child’s lens cannot filter out UV rays and so more radiation reaches the retina. At the same time, decades of sun exposure make older people’s eyes much more prone to visual problems and disease.
  •     Eye color- The color of the eye appears to play a role, with some studies suggesting that blue eyes are at more risk for UV damage than brown eyes. The protective pigment melanin may be the key detail – blue irises have less of it – and a higher incidence of age-related macular degeneration may be one consequence.

Prevent Blindness strongly recommends wearing UV-blocking sunglasses as well as a brimmed hat to provide the best protection against UV rays. Sunglasses should:

  •     reduce glare
  •     filter out 99-100% of UV rays
  •     be comfortable to wear
  •     not distort colors

“Spending time outdoors offers many health benefits. We encourage adults and children to wear the proper UV protection for their eyes to keep them safe and healthy today, and in the years to come,” said Jeff Todd, president and CEO of Prevent Blindness.

For more information on UV eye protection, please visit the Prevent Blindness dedicated webpage at PreventBlindness.org/sun-and-vision, or call (800) 331-2020.

About Prevent Blindness
Founded in 1908, Prevent Blindness is the nation’s leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs and research. These services are made possible through the generous support of the American public. Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America. For more information, visit us at preventblindness.org, and follow us on Facebook, Twitter, Instagram and LinkedIn.

Contact Author

SARAH HECKER

Prevent Blindness
312.363.6035

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

Mindray North America Slated to Connect Health and Care at HIMSS

March 11, 2022 (Global News Distribution) -

Global developer of leading-edge medical solutions invites attendees to experience an interoperability showcase featuring Pregnancy and Surgical Complications at HIMSS.

Mindray, a global developer of technologies and solutions for patient monitoring, anesthesia, and ultrasound today announced that they will attend the Healthcare Information and Management Systems Society (HIMSS) 2022 Annual Meeting live in Orlando, Florida. Mindray’s portfolio of medical and interoperability solutions optimize clinician’s workflow through intuitive systems and enhance patient care with reliable and safe functionality. All HIMSS attendees are invited to visit Booth 8240 in the Interoperability Showcase Hall E and experience Mindray’s technology in the “Pregnancy and Surgical Complications” interoperability showcase.

“We are excited to attend HIMSS 2022 this year and showcase Mindray’s interoperability solutions and demonstrate how today’s healthcare technology efficiently distributes the patient record throughout the care path and the healthcare enterprise,” said Preet Singh, Sr. Technical Marketing Manager, Interoperability and Partnerships. Singh continued, “Our interoperability showcase features the care journey of a mother and newborn and highlights the importance of providing gapless medical documentation as they move across multiple areas of the hospital receiving care.”

Technologies highlighted in the interoperability showcase include:

  • A9 Anesthesia Machine: The new A9 Anesthesia Workstation introduces technology to maximize patient safety, help improve patient outcomes, complement the way clinicians work best, and increase efficiency.
  • BeneVision N1 Transport Monitor/Module: A compact 3-in-1 solution designed to adapt to the monitoring needs across an entire hospital and serves as a comprehensive multi-parameter module, a powerful transport monitor, and a versatile bedside monitor – all in one.
  • BeneVision N17 Patient Monitor: A premier solution to satisfy patient monitoring needs across diverse care settings. With a platform-wide modular design, expansive parameter options, and specialized Clinical Assistance Applications (CAAs) to support clinical excellence and align with the organizational cost of ownership goals.
  • eGateway: Mindray’s solution to integration between patient monitoring and life support systems and the various hospital electronic medical record systems.

Mindray believes in solutions that address clinicians’ biggest monitoring challenges, such as patient safety, improved patient outcomes, and streamlined workflows. Focused on the human side of healthcare and the clinician’s role in providing best-in-class patient care, Mindray creates products suited to clinician’s needs that elevates patient safety and care. Team members will be onsite throughout the exhibit detailing Mindray’s positive impact in the OR, ICU, and NICU environments and addressing questions from attendees. Visit Mindray at booth 8240 to learn more about these innovative interoperability solutions.

About Mindray
Mindray is a leading developer, manufacturer, and supplier of medical device solutions and technologies used in healthcare facilities around the globe. We believe we can change lives by making the most advanced healthcare technology attainable for all. We do this by empowering healthcare professionals through innovative, high-value solutions that help create the next generation of lifesaving tools across three primary business segments: medical imaging, patient monitoring and life support, and in-vitro diagnostics. Mindray maintains its global headquarters in Shenzhen, China; Mindray North America is headquartered in Mahwah, New Jersey. Our Ultrasound Innovation Center is located in San Jose, California, with additional facilities in major international markets around the world. For more information, please visit http://www.mindray.com.

Contact Author

SONDRA KAUFMAN

Mindray North America
201.995.8047

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

Recognize Red Flags for Your Heart Health

March 7, 2022 (Global News Distribution) -

(Family Features) A red flag is a common signal indicating potential danger or trouble, and that includes issues related to your health.

An educational campaign sponsored by Amarin Pharma Inc. encourages patients who have had a heart attack or stroke to “Raise a Red Flag” with their health care providers to learn more about their increased risk of another serious cardiovascular event.

Consider this information to help protect your heart health by understanding more about possible risk factors and how to reduce them.

Red Flags for Increased Risk

According to the American Heart Association, every 40 seconds someone in the U.S. has a heart attack or stroke. Research shows people who have had a heart attack are up to 50% more likely to have another cardiovascular event or heart procedure within a year.

In addition to having a medical history that includes heart disease or other heart-related incidents, like heart attack or stroke, there are other red flags that indicate you may be at increased risk for another cardiovascular event.

Other risk factors may be beyond your control, but awareness may help you manage your risk. A family history of heart disease puts you at greater risk, as does increasing age and other health conditions and lifestyle choices.

Reduce Your Risk

While you can’t control your age or genetics, you can make lifestyle adjustments and explore medications and other ways to manage your heart health, especially if you’ve already experienced heart health problems.

“Treating heart disease and stroke is a partnership and each individual’s doctor and health care team will develop a treatment plan that’s right for that patient,” said cardiologist Dr. John Isaac, an Amarin consultant. “For my patients who have already had a cardiovascular event, such as a heart attack or stroke, I often prescribe VASCEPA® (icosapent ethyl) to reduce the risk of another life-threatening cardiovascular event.”

The medication is used along with certain medicines (statins) to reduce the risk of heart attack, stroke and certain types of heart issues requiring hospitalization in adults with cardiovascular disease or diabetes and two or more additional risk factors for heart disease. It is not known if it is safe and effective in children.

In a clinical study, patients treated with VASCEPA had fewer cardiovascular events (17.2%) compared to those who took placebo (22%). Itis the only FDA-approved prescription oral medication clinically proven to reduce cardiovascular risk by up to 25% when taken along with certain medicines, such as statins.

You shouldn’t take VASCEPA if you’re allergic to icosapent ethyl or any inactive ingredient in the medication. Stop taking it and seek medical help if you have symptoms of an allergic reaction. Serious side effects may occur like heart rhythm problems and bleeding. Tell your doctor if you experience an irregular heartbeat or other heart rhythm problems. Other possible side effects include muscle and joint pain.

For more information, including Prescribing Information, Patient Information, Indications, Limitations of Use and Important Safety Information, visit raisearedflag.comto get your questions answered and schedule a health care provider appointment either in-person or via a telehealth visit.

Photo courtesy of Adobe Stock

IMPORTANT SAFETY INFORMATION

WHO SHOULD NOT TAKE VASCEPA?

  • Do not take VASCEPA if you are allergic to icosapent ethyl or any of the ingredients in VASCEPA.

WHAT ARE THE POSSIBLE SIDE EFFECTS OF VASCEPA?
VASCEPA may cause serious side effects, including:

  • Heart rhythm problems (atrial fibrillation and atrial flutter).

Heart rhythm problems which can be serious and cause hospitalization have happened in people who take VASCEPA, especially in people who have heart (cardiovascular) disease or diabetes with a risk factor for heart (cardiovascular) disease, or who have had heart rhythm problems in the past. Tell your doctor if you get any symptoms of heart rhythm problems such as feeling as if your heart is beating fast and irregular, lightheadedness, dizziness, shortness of breath, chest discomfort or you faint.

  • Possible allergic reactions if you are allergic to fish or shellfish.

Stop taking VASCEPA and tell your doctor right away or get emergency medical help if you have any signs or symptoms of an allergic reaction.

  • Bleeding.

Serious bleeding can happen in people who take VASCEPA. Your risk of bleeding may increase if you are also taking a blood thinner medicine.

If you have liver problems and are taking VASCEPA, your doctor should do blood tests during treatment.

The most common side effects of VASCEPA include:

  • Muscle and joint pain
  • Swelling of the hands, legs, or feet
  • Constipation
  • Gout
  • Heart rhythm problems (atrial fibrillation)

These are not all the possible side effects of VASCEPA. Call your doctor for medical advice about side effects. You may report adverse events (i.e. side effects) or product complaints by contacting AmarinConnect at 1-855-VASCEPA (1-855-827-2372), emailing AmarinConnect@Amarincorp.com, or calling the FDA at 1-800-FDA-1088.

Tell your doctor if you take medicines that affect your blood clotting (anticoagulants or blood thinners).

For more information on VASCEPA, click here to see the full Patient Information or call 1-855-VASCEPA (1-855-827-2372).

Michael French
mfrench@familyfeatures.com
1-888-824-3337
editors.familyfeatures.com

About Family Features Editorial Syndicate

A leading source for high-quality food, lifestyle and home and garden content, Family Features provides readers with topically and seasonally relevant tips, takeaways, information, recipes, videos, infographics and more. Find additional articles and information at

Culinary.net

and

eLivingToday.com

SOURCE: Family Features

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

EarPeace Creates a Custom Hearing Protection Line in Collaboration with NPR

February 16, 2022 (Global News Distribution) -

EarPeace announced they are collaborating with NPR to create a line of custom branded earplugs in order to reduce noise-induced hearing loss (NIHL) amongst artists and music fans.

Today, EarPeace announced they are collaborating with NPR to create a line of custom branded earplugs in order to reduce noise-induced hearing loss (NIHL) amongst artists and music fans.

For the collaboration, NPR x EarPeace will include the newly patented EarPeace PRO earplugs. EarPeace PRO features a contoured design that conforms to the natural shape of the ear canal. Combined with the finely tuned acoustic mesh filter that precisely replicates the sound signature, PRO delivers a true-to-life audio experience at a safe volume for discerning artists and music fans.

“I am a native Washingtonian and die-hard NPR fan. Chances are 50/50 whether I’m listening to music or the dulcet tones of NPR news keeping me informed. Working with NPR to keep the community’s hearing healthy is a profound honor,” said Jay Clark, Founder and CEO of EarPeace. “When I first launched EarPeace, one of the first people I approached to test drive the plugs was NPR Music’s Bob Boilen. If anyone knows live shows and the subtlety of music, it’s Bob.”

“EarPeace are among the best earplugs out there and have used them literally at over a thousand shows. My ears thank you,” stated Bob Boilen, Creator/Host of All Songs Considered and Tiny Desk Concerts.

According to the Centers for Disease Control and Prevention (CDC), in less than five minutes at a rock concert, NIHL has already begun. In the past year, roughly 25 million Americans have experienced tinnitus. As a result, hearing loss remains the third most common chronic physical condition in the United States and is twice as prevalent as diabetes or cancer.*

“Unless I’m mixing and recording at the Tiny Desk, I’m using hearing protection at concerts. EarPeace has been one of my go-to brands for years. Do your future self a favor and protect your ears,” said Josh Rogosin, Tiny Desk Audio Engineer and Technical Director for NPR Music, who, even prior to the collaboration with EarPeace, has been an advocate for safe listening with hearing protection.

Recently granted their second patent for the proprietary design of their earplugs following their utility patent, PRO resolves a common problem in traditional earplugs that contain rigid components by eliminating the mismatch between the shape of the ear and plug. The earplugs use less material to optimally expand in the ear canal, minimizing unwanted bunching and slit leaks. In addition to the higher level of comfort, the oval, offset wave shape of their patented design permits the filters to perform at peak capacity.

On a mission to save the world’s hearing and prevent NIHL, EarPeace hasn’t stopped at revolutionizing hearing protection options – they continue to lead the charge in how people value their hearing health as well as efforts to reduce the epidemic of hearing loss and tinnitus. EarPeace is trusted by NPR, Metallica, RedBull, Lollapalooza, and more.

For more information on the EarPeace, please visit: https://www.earpeace.com.

###

About EarPeace:
EarPeace revolutionized hearing protection in 2008 with a discreet, comfortable, high-fidelity earplug built not only for musicians, but for all the fans at the event. This same technology was customized for motorsports, travel, anyone that needs a safety product, and for everyone that needs a good night’s sleep. The innovation by EarPeace continues today with new patents, products, technologies, and accessories designed to “enhance your experience.” Festivals, motorcycle rallies, and events all over the world depend on EarPeace to keep their stars and fans safe, comfortable, and ready for the next event. EarPeace’s promise is simple – you will hear and feel better when you wear EarPeace. For more information, visit: https://www.earpeace.com.

*Based on calculations performed by NIDCD Epidemiology and Statistics Program staff: (1) tinnitus prevalence was obtained from the 2008 National Health Interview Survey (NHIS); (2) the estimated number of American adults reporting tinnitus was calculated by multiplying the prevalence of tinnitus by the 2013 U.S. Census population estimate for the number of adults (18+ years of age)(Blackwell DL, Lucas JW, Clarke TC. Summary health statistics for US adults: National Health Interview Survey, 2012. Vital Health Stat 10. 2014;260:1-161.)

Contact Author

NATALIE MIKOLICH

EarPeace
5614144047

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

“Health City” – Aimedis publishes Health-Metaverse and soon opens the first clinic in it

January 5, 2022 (Global News Distribution) -

The blockchain-based medical company Aimedis is entering the metaverse. To this end, they are currently working on their own area in the digital space, including their own chain of clinics.

The metaverse has arrived in the mainstream at least since the media rebranding of Facebook. The digital parallel world has the potential to digitize entire branches of industry – including the medical sector. Aimedis has also recognized the trend and is now announcing its own plans for the Metaverse. Specifically, it is about establishing one’s own medical area in the virtual world, where patients, medical staff, clinics, universities and companies from the pharmaceutical industry or insuraces, among others, have the opportunity to interact digitally with one another.

In the Aimedis Health City, as the Metaverse is called, other hospitals will also be able to open clinics in the virtual world and rent or buy entire areas. Lease agreements can then be concluded via Aimedis DataxChange, the in-house NFT marketplace, for example.

As a first step, the company from the Netherlands and the United Arab Emirates will place its first own hospital in the Metaverse – the “Alpha Hospital”. For example, therapy sessions, consultations, visits to the doctor and interactions between patients take place here, but also students, medical staff and laypeople are trained. A dedicated AI with the sonorous name AVA (Aimedis Virtual Assistant) guides you through the virtual space and brigdes the ecosystem of Aimedis with the metaverse.

The native token AimX also fulfills an important function as a means of payment in the Aimedis metaverse. The use of the payment method is not compulsory, but offers users advantages in the form of discounts, among other things and perks. In addition, AimX recently launched on ProBit (AIMX / USDT) and Pancakeswap (AIMX / BUSD). In addition, the price of the token can now be tracked on both Coingecko and CoinMarketCap.

First demo available on Steam from January

Aimedis is currently working flat out on a first demo version of the Health City. A first foretaste will be presented on January 24th, 2022 at the Arab Health 2022 in Dubai. Shortly afterwards, interested parties should also be able to download the demo version on the Steam game platform. Aimedis is currently developing its Metaverse based on the Unity Engine. Furthermore, Aimedis weighs up the use of the Unreal Engine 5. The development software is to be used increasingly for games on the next-gen Xbox Series X and PlayStation 5 consoles.

The connection of IoT devices and trackers will also play a role in Health City.

An exact launch date for the Aimedis Health City is not yet been disclosed. However, the company anticipates the start of the first areas and clinics in the first quarter of the coming year.

Team
Aimedis

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

Teeccino Continues Mission to Help Customers Achieve Optimal Health With Launch of New Wellness Box

January 4, 2022 (Global News Distribution) -

America’s Number One Coffee Alternative and Roasted Herbal Tea Brand Rolls Out New Sampler Box To Support Customers Wellness Journey

Teeccino, known for bold tasting, roasted herbal coffees and teas, has launched a caffeine-free Wellness Box to help customers ring in the New Year with optimal health. The new box features the brand’s Wellness Herbal Coffee Sampler, Prebiotic Superboost™ Herbal Tea Sampler and Mushroom Adaptogen Herbal Tea Sampler.

  • Teeccino’s Wellness Herbal Coffee sampler includes Teeccino’s new wellness blends designed to promote optimal health while providing delicious enjoyment. Six blends feature renowned mushroom and adaptogenic herbs to help your body adapt to stress and three blends provide Prebiotic SuperBoost™ for optimal gut health.
  • Teeccino’s Prebiotic Superboost™ blends include the naturally prebiotic chicory root as well as a concentrated, plant-based blend of two prebiotics, vegan GOS, gluco-oligosaccharide. and organic XOS, xylo-oligosaccahride, which result in an even greater beneficial impact on overall gut health. The Prebiotic Superboost™ flavors, which are perfect for coffee drinkers having problems with coffee’s acidity, include: Macadamia Nut, Dark Chocolate, and Mango Lemon Balm.
  • Teeccino’s Mushroom Adaptogen blends are rich and bold in flavor with adaptogens aimed at protecting the mind & body by boosting one’s immune system. Adaptogens help the body adapt to different kinds and levels of stress, while increasing endurance and energy production. The Mushroom Adaptogen flavors include; Tremella Tulsi Cardamom, Cordyceps Schisandra Cinnamon Berry, Chaga Ashwagandha Butterscotch Cream, Turkey Tail Astragalus Toasted Maple, Lion’s Mane Rhodiola Rose, and Reishi Eleuthero French Roast.

“At Teeccino we’re focused on bringing the healthiest herbal tea and coffee alternatives to customers,” says Caroline MacDougall, Teeccino’s founder. “While this is something we prioritize all year round, we want to help customers easily join us on this journey while building their New Year goals. Our new Wellness Box will help people jump start the year on a healthy and refreshed foot, one cup at a time.”

For those looking to further explore Teeccino’s wellness offerings, and detox deliciously, the Dandelion Herbal Tea Sampler Box, features two cups each of all six top selling Teeccino Dandelion flavors. Savor the swirl of sweet dates and figs in Dandelion Caramel Nut, the deep-roasted coffeelike flavor in Dandelion Dark Roast, the ginger and cinnamon spiciness in Dandelion Red Chai, the licorice sweetness with turmeric pungency in Dandelion Turmeric, the cool ultra-refreshing notes of peppermint with chocolate in Dandelion Mocha Mint, and the tropical nuttiness of coconut and almonds in Dandelion Coconut. These Dandelion blends feature antioxidants from carob, dandelion, dates, figs, almonds, ramón seeds, peppermint, cocoa, cinnamon, ginger, cardamon, black pepper, cloves, turmeric, while containing heart-healthy potassium and soluble fiber. Inulin from chicory feeds your probiotics, the beneficial microflora that improve gut health, regularity and supports your immune system. Inulin extracts naturally into your cup from chicory and dandelion roots during brewing.

Teeccino is a family-owned business dedicated to supporting consumers on their journey to optimal health. Committed to authenticity, transparency, and sustainable sourcing of its ingredients, Teeccino continues to reach new heights of innovation with unique, expertly blended botanicals that produce natural wellness effects. With delicious flavor from its roasted herbs, roots, fruits, and nuts, Teeccino is ground to brew like coffee or steep like tea. Their coffee alternatives and herbal teas are made with the highest quality, non-GMO, organic ingredients and prebiotics without any artificial flavors, preservatives, chemicals, or stimulants, to meet the needs of those who want rich, bold flavor without the undesirable effects of caffeine and acidity.

Teeccino’s new Wellness Box can be found directly on their site. For more information about Teeccino, visit Teeccino.com or follow @Teeccino on Instagram.

About Teeccino
Caroline MacDougall launched Teeccino at Expo West in 1995 to satisfy both coffee and tea drinkers alike with its rich, bold full-bodied flavor and its many health benefits. Nationally distributed in specialty grocery chains like Whole Foods, Sprouts, and Wegmans as well as etailers like Amazon and Vitacost, Teeccino’s 36 flavors and counting are the #1 coffee alternatives in the coffee set and the premier line of roasted herbal teas in the tea set. Unique among all teas and coffees, people often ask, is Teeccino coffee or is it tea? The answer is simple, it’s Teeccino!

Contact Author

HANNAH FOSTER

Konnect Agency
+1 4073422833

For more latest News click here

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

NEXT Big Merger is Underway on the NASDAQ: JUPW Signs Definitive Agreement to Merge with Next Frontier Pharmaceuticals

December 9, 2021 (Global News Distribution) -

Jupiter Wellness to Merge with Next Frontier Pharmaceuticals. Leading Drug Developer & Manufacturer of Synthetic Cannabinoid Pharmaceuticals: (NASDAQ: JUPW)

Jupiter Wellness, Inc. (NASDAQ:JUPW), announced today it has signed a definitive agreement to acquire Next Frontier Pharmaceuticals, Inc. (“Next Frontier Pharmaceuticals”), through a merger with a subsidiary of Jupiter Wellness. Under the terms of the transaction, Next Frontier Pharmaceuticals’ stockholders will receive shares of Jupiter Wellness convertible preferred stock that will be convertible into the common stock of Jupiter Wellness and no cash. The transaction, which has been unanimously approved by the board of directors of both companies, is expected to close in the first quarter of 2022.

• Owner of SYNDROS®(dronabinol), the only US-based FDA approved CII Tetrahydrocannabinol (THC), a liquid cannabinoid used in adults to treat: Chemotherapy Induced Nausea and Vomiting (CINV) associated in adult patients who have failed to respond adequately to conventional antiemetic treatments; and Anorexia associated with weight loss in adult patients with Acquired Immune Deficiency Syndrome (AIDS)

• 83,000 square foot manufacturing facility in Texas is FDA registered and licensed by the U.S. DEA to manufacture Schedule I to III controlled substances in a cGMP facility, with a DEA-exemption permit to export globally

• Five FDA-registered Investigational New Drugs

• Seminal patents in organic and synthetic cannabinoids

• Pending license approval to manufacture psychedelic pharmaceuticals

Upon the closing of the transaction, the combined company intends to become a leading drug developer and manufacturer of pharmaceutical cannabinoids and psychedelics with a growing portfolio of drug products and intellectual property.

Next Frontier Pharmaceuticals owns the only U.S.-based FDA approved CII Tetrahydrocannabinol (THC), a liquid cannabinoid, SYNDROS®, used in adults to treat: CINV in adult patients who have failed to respond adequately to conventional antiemetic treatments; and Anorexia associated with weight loss in adult patients with AIDS. Next Frontier Pharmaceuticals is also pursuing a 505(b)(2) approval pathway with the FDA for several Investigational New Drugs (INDs) for indications including opioid withdrawal, pain, migraines, and nausea and vomiting associated with chemotherapy. The Company’s 83,000 square foot manufacturing facility in Texas is FDA registered and licensed by the U.S. DEA to manufacture Schedule I to III controlled substances in a cGMP facility. The facility currently operates as a contract manufacturer of active pharmaceutical ingredients (APIs). Next Frontier Pharmaceuticals also has a robust portfolio of patents and patents pending on organic and synthetic cannabinoids.

“Jupiter Wellness was established with a vision to become a leading pharmaceutical cannabinoid company. Today, with the signing of the merger agreement with Next Frontier Pharmaceuticals, we will have the foundational drug development and formulation team and manufacturing assets to become such a leader. With its industry-leading cannabinoid platform, innovative products, and pipeline, we strongly believe that Next Frontier Pharmaceuticals positions us well for long-term stockholder value creation,” said Brian John, Chief Executive Officer of Jupiter Wellness. “We are joining with a world-class team of executives and board members with a strong track record of execution that share a passion for pursuing differentiated therapies based on cannabinoids and psychedelics.”

“With assets that have been developed over the last 10 years, Next Frontier Pharmaceuticals believes it is well positioned to have a leadership position in cannabinoid science, including the only U.S.-based FDA approved CII Tetrahydrocannabinol (THC), a liquid cannabinoid and one of the largest captive synthetic cannabinoid manufacturing facilities in the world. With our FDA approved SYNDROS® drug, we intend to expand our platform of drug products to create novel therapies for pain, inflammation, and insomnia, among other ailments. Given our focus, we believe that Jupiter Wellness is an ideal growth partner that is committed to supporting our commercial efforts, as well as ongoing clinical and research programs,” said Shannon Soqui, Executive Chairman of Next Frontier Pharmaceuticals. “We have a shared vision of developing and commercializing innovative medicines that utilize cannabinoids and psychedelics. As a public company, Next Frontier Pharmaceuticals believes it will now have the resources and opportunity to reach and impact more patients through a broader portfolio of cannabinoid-focused therapies than ever before.”

Creates a Leader in Pharmaceutical Cannabinoid Drug Development and Manufacturing

 Drug Development Platform Expansion: The transaction enables the expansion of drug development and formulation capabilities focused on cannabinoids and psychedelics. With SYNDROS®, Next Frontier Pharmaceuticals will attempt to extend the formulation for use for pain and inflammation, among other indications. The collective Jupiter Wellness and Next Frontier Pharmaceuticals teams will bring highly complementary expertise to a pro forma pipeline of nine clinical development programs for pain and migraines, among other indications.

 Synthetic Cannabinoid and Psychedelic Manufacturing: Creates the leading platform for active pharmaceutical ingredient manufacturing based on synthetic cannabinoids and psychedelics. With a DEA-exemption permit to export globally, and with product manufactured in a cGMP FDA registered facility that holds both DEA licenses and Board of Pharmacy permits, the platform is uniquely positioned for growth given the difficulty, cost, and time to obtain such capabilities.

 Seminal Patents in Organic and Synthetic Cannabinoids: Next Frontier Pharmaceuticals has two patents that have received notices of allowance including a foundational method of cannabigerol (CBG) synthesis and a unique broad spectrum hemp powder, and 14 patents pending surrounding cannabinoid synthesis and cannabis production methodologies.

 Exceptional Management Team and Board: The Next Frontier Pharmaceutical team includes a roster of Fortune 500 executives with a long history in pharmaceuticals and cannabinoids, as well as public company management, reporting and corporate governance experience, and a board advisor that was formerly at GW Pharmaceuticals.

 Expected to Deliver Substantial Stockholder Value: The combination is expected to provide accelerated revenue and earnings growth and to be accretive in the first full year of combined operations and substantially accretive thereafter.

Transaction Terms

Under the terms of the agreement, Next Frontier Pharmaceuticals’ stockholders will be entitled to receive convertible stock of Jupiter Wellness that is convertible into 65,000,000, shares of Jupiter Wellness common stock and no cash at the closing of the transaction. Such shares will be subject to a six-month standard lock-up agreement. In connection with the transaction, Jupiter Wellness has loaned $10.2 million to Next Frontier Pharmaceuticals under a note secured by Next Frontier Pharmaceuticals’ Texas-based synthetic cannabinoid manufacturing facility.

Closing Conditions

The transaction has been unanimously approved by the Boards of Directors of both companies and is subject to the approval of Jupiter Wellness stockholders and other customary closing conditions, including regulatory approvals. Subject to the satisfaction or waiver of the closing conditions, the transaction is expected to close in the first quarter of 2022.

Conference Call Details

The two companies will host a conference call on Thursday, December 9th at 4:00 PM ET to discuss this transaction. The live webcast may be accessed from the Investors section of Jupiter’s website at www.jupiterwellness.com. Please connect prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary. Investors may participate in the conference call by dialing 561-462-3946. An archived version of the conference call will be available for at least one week in the Investors section of Jupiter’s website at www.jupiterwellness.com.

Advisors

Lucosky Brookman LLP, led by Joe Lucosky and Adele Hogan, is serving as legal counsel to Jupiter Wellness.

• The burn care market was valued at $2.1 billion in 2020 and is expected to grow at a CAGR of 7% from 2021 to 2028 driven by rising incidence of burns, favorable reimbursement policies, and technological advancement. Developer of CBD Treatments for the Growing Global Skin Care Market.

• Multiple Clinical and Commercial Milestones Recently Achieved on the Company’s Proprietary Product Lines.

• Pro Golf Hall of Fame Legend Ernie Els Extends Endorsement Deal.

 Submitted Pre-IND Meeting Request with US FDA for Proposed Clinical Program of JW-100 as a Treatment for Mild to Moderate Eczema.

Jupiter Wellness, Inc. (NASDAQ: JUPW) is a leading developer of cannabidiol (CBD) based medical therapeutics and wellness products. The JUPW clinical pipeline of prescription CBD-enhanced skin care therapeutics address indications including eczema, burns, herpes cold sores, and skin cancer. JUPW generates revenues from a growing line of proprietary over-the-counter skincare products including its flagship CaniSun™ sunscreen and other wellness brands sold through its robust distribution platform.

JUPW is NASDAQ listed and has an attractive share structure with only
22,927,465 shares currently outstanding.

 Shareholder Update on Multiple Clinical & Commercial Milestones Plus Upcoming Television Advertisement

On October 27th JUPW provided a comprehensive shareholder update on its advancing clinical programs and commercial progress. The updated included the following details:

Commercial:

The JUPW product Photocil™ (“Phototherapy in a bottle”), a patented topical Over-the-Counter drug for the treatment of psoriasis and vitiligo is expected to launch in Q1 2022. Photocil was licensed from Applied Biology. The clinical efficacy of Photocil™ in the treatment of psoriasis and vitiligo has been published in peer-reviewed medical journals. Photocil has been assigned the following NDC numbers by the FDA for each product:

 82301-001-001 (Atopic Dermatitis)

 82301-002-001 (Psoriasis)

 82301-003-001 (Vitiligo)

Clinical:

US FDA Filings for JW-100 as a Treatment of Eczema

JUPW recently submitted a pre-IND package for JW-100 as a prescription drug for the treatment of mild-to-moderate atopic dermatitis (eczema). JUPW anticipates a pre-Investigation New Drug (IND) meeting with the US FDA in Q4 2021. In a prior early study, JW-100 cleared or reduced eczema following 2 weeks of use, suggesting that through its unique mechanism of action it may potentially prove superior to existing prescription drugs for the treatment of eczema.

Phase III Head-to-Head Study of JW-100C in Eczema

A head-to-head Phase III double-blinded, placebo controlled clinical trial designed to evaluate the superiority of JW-100 to Eucrisa (an FDA approved topical drug) in adult patients with mild-to-moderate eczema expects the first patient enrolled in Q4 2021.

JW-200 Clinical Study in Actinic Keratosis to Complete Enrollment Q1 2022

An investigational clinical study with a protocol similar to an FDA Phase I is enrolling 115 adults diagnosed with actinic keratosis. Enrollment is expected to be completed by the beginning of 2022 and data will be used in preparation for an FDA IND filing.

JW-300 Clinical Study in Burns to Complete Enrollment Q4 2021

A double-blinded, placebo controlled investigational study in Europe and Asia with a protocol similar to an FDA Phase I is enrolling 50 patients with newly diagnosed first degree burns. Resulting data will be used in preparation for an FDA IND filing. Enrollment is expected to be completed by the end of 2021.
“Based on our acquisition and development strategy. Jupiter Wellness has short-term product opportunities and an extensive clinical pipeline conducting double-blinded, placebo controlled clinical trials to unequivocally establish efficacy of our novel and proprietary products for both OTC and prescription drugs,” stated Dr Glynn Wilson, Jupiter’s Chief Scientific Officer. “Jupiter Wellness is committed to providing rapid and consistent relief for the majority of people suffering from a number of skin indications, including eczema, psoriasis, and vitiligo. Jupiter Wellness is also committed to developing approaches that measure individual gene expression that can be used to determine the most appropriate patients for treatment and the outcomes of therapies.”

 Multi-Year Extension of Endorsement Agreement with Pro Golfer Ernie Els

On September 8th JUPW announced a multi-year extension of its endorsement agreement with PGA Golf Legend Ernie Els. Els, known as “The Big Easy”, will help promote the JUPW patent pending CaniSun Suncare Product Line for two additional years. The CaniSun product line offers the highest quality suncare products infused with CBD.

Pursuant to the agreement, JUPW will extend its agreement with renowned golfer Ernie Els, who will act as a brand ambassador of the JUPW unique, one-of-a-kind Suncare products. The campaign is seen as CaniSun partnering with one of the best and well-liked athletes in the sport of golf. The campaign focuses on providing premium suncare protection for everyone from elite athletes like Ernie Els to the everyday weekend warrior.

“Because I spend so much time in the sun, I always hit the golf course with CaniSun. I’m constantly looking for the most effective products, and CaniSun consistently works well for me, so it’s my first choice,” Els stated. “I’ve been using CaniSun sunscreen and I love the product. This is an easy endorsement for someone who is in the sun as much as I am. Extending the relationship made sense.”

 Submitted a Pre-IND Meeting Request with the US FDA for its Proposed Clinical Program of JW-100 as a Treatment for Mild to Moderate Eczema
On August 23rd JUPW announced it has submitted a pre-IND (Investigational New Drug) meeting request with the U.S. Food and Drug Administration (FDA) in support of its JW-100 drug development program the treatment of patients with mild to moderate Eczema .

The benefits of holding a pre-IND meeting are to receive early FDA feedback on proposed preclinical and clinical study plans confirming strategy for IND submission. The FDA’s statistics show that this can significantly reduce overall development times which impacts time to market.

The Global Eczema (atopical dermatitis) treatment market is valued at $10 billion and expected to grow at a CAGR of 13% from 2020-2025. 31.6 million Americans or roughly 10% of the population suffer from Eczema. 86% are not satisfied with their current treatment.

Through the JUPW research and development program, it has shown that in a double-blinded, placebo controlled clinical trial, JW-100 significantly reduced ISGA scores in 50% of adult patients suffering from eczema and JW-100 cleared or reduced eczema following 2 weeks of use.
For additional information on Jupiter Wellness, Inc. (JUPW) visit www.jupiterwellnessinc.com.

All products mentioned in this article are THC-free and compliant with the 2018 farm Bill

DISCLAIMER: FrontPageStocks/CorporateAds.com (CA) is a third-party publisher and news dissemination service provider. FPS/CA is NOT affiliated in any manner with any company mentioned herein. FPS/CA is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FPS/CA’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. FPS/ CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. FPS/CA has been compensated $500 by the company for dissemination of this Article.

Disclaimer/Safe Harbor:

These news releases and postings may contain forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect

SOURCE: CorporateAds.com

JUPW
Jupiter Wellness, Inc
+1 561-244-7100

For More News

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

Kilo Health Named the 2nd Fastest Growing Company in All of Central Europe: The Deloitte Technology Fast 50

December 7, 2021 (Global News Distribution) -

Kilo Health Ranks #2 in the Deloitte Technology Fast 50 of Growing Companies in Central Europe

Kilo Health, one of the leading digital health companies, was recently named the second fastest-growing technology company in central Europe in Deloitte’s “2021 Technology Fast 50 Central Europe” ranking. This list measures the rapidly ascending public and private leaders in the tech world and recognizes the standouts in this up-and-coming region.

In less than 3 years, Kilo Health has grown its product portfolio to more than 4 million clients and 15 products in digital health, wellness, and chronic disease prevention. In 2021, the company grew its team to more than 500 people and opened three new offices, including new operations in Berlin, Vilnius, and Kyiv, bringing the company to five offices as of yet. Kilo has also become a member of the Digital Therapeutics Alliance and Matter Community.

“All this comes from being bold, unafraid to experiment and stand out. By combining progressive ideas with scientific proof and technology, we can create innovative products that help people treat and prevent chronic diseases. We’re also entirely bootstrapped, which gives us full freedom to decide what risks we choose to take. We’ve never been afraid of taking risks or failing – this recognition from Deloitte shows that we’re definitely on the right track.” – said Tadas Burgaila, CEO at Kilo Health.

As medical costs rise in many parts of the world, people crave affordable and accessible options to prevent illness and manage their health without having to schedule constant visits to their doctor. They want practical advice and information that gives them a broader perspective about how different parts of the body and mind determine how they feel on a regular basis.

The team at Kilo Health saw that a major overhaul was needed in terms of how information was provided and what tools could be given to patients who needed guidance far more than they needed judgment. That’s why the company’s products connect patients with up-to-date data that can help them stay on top of both short- and long-term goals and complement the existing healthcare system, providing medical professionals with the latest information.

Kasparas Aleknavicius, Kilo Health’s Head of Medical Affairs, said, “I think the brightest future, looking from a business angle, awaits solutions that provide personalized care, no matter the issue a person wants to solve.”

By bringing affiliated conditions under the same umbrella, patients can access more from one place, making it easier to keep up with daily habits. It’s this kind of insight that has helped the company grow its customer base and attract employees into the fold.

About Kilo Health

Kilo is one of the leading digital health and wellness companies globally. With 4+ million clients worldwide (the majority in the United States), strong technology, and a digital marketing platform, It provides unparalleled opportunities for entrepreneurial talents and visionaries to build digital health products of the future. It has grown from 7 to 500 bright talents in three years and aims to become the most loved digital health and wellness product suite globally.

CONTACT:

Kilo Health
https://kilo.health/
media@kilo.health

SOURCE: Kilo Health

Read More News

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection

BlueSky Synergy Announces Formal Release of Version 5.18, Becomes First Platform to Provide Hospitals with Complete Control of Subcontractor Relationships

December 7, 2021 (Global News Distribution) -

BlueSky Synergy announced today its formal release of BlueSky Medical Staffing Software Version 5.18. Due to the recent rise in travel nurse staffing rates, the technology released today becomes the first platform to provide hospitals complete control of subcontractor relationships.

BlueSky Medical Staffing Software’s easy-to-use interface is designed for seamless communication between nurses, scheduling departments, compliance staff, and back-office finance teams. The system was created to integrate with multiple human resource, time and attendance, and credential management platforms paving the way for reduced labor costs in an industry fraught with skyrocketing demands.

The beta testing of this technology has been largely successful; BlueSky’s recent beta test with the Adventist Healthcare System on the west coast has successfully brought all contract labor management in-house. Savings from the automation has provided uniformity of nurse and agency documentation, and provided real-time reporting for spend by department and historical trend analysis. The early stages provided invaluable feedback for best practices and deeply integrated reporting metrics.

Tim Teague, President of BlueSky, had this to say of the innovation: “The acceleration of nurse staffing costs is creating both budgetary and morale problems within the healthcare community. It is important that these healthcare entities begin to move toward platforms that connect them more closely to the limited supply of nurses.”

The Adventist Healthcare beta test in particular was used to successfully automate and consolidate all contingent personnel relationships across a 28-hospital system to provide centralized control and reporting with the added benefit to quickly establish their own “self-service” agency.

The release today marks a much needed first for an industry inundated with staffing woes. If you would like to learn more about BlueSky and this breakthrough, be sure to visit BlueSky’s website or contact BlueSky directly.

Contact Author

MIA FOLEY

BlueSky Medical Staffing Software
615-647-6697

Read More News

Media Contacts:


Full Name
Company
Phone Number
Website
Email

Compose your email to at .


  Spam Protection